NEW YORK (GenomeWeb) – A new report filed with German healthcare regulators currently sees no benefit from gene expression-based breast cancer tests used in breast cancer treatment decisions.
Submitted on Oct. 31, 2016 by the Institute for Quality and Efficiency in Healthcare (IQWiG) — a contractor for the German government that evaluates new medical interventions — the report became publicly available last month.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
